RNA logo

RNA
Atrium Therapeutics Inc.

1,620
52W High
$16.77
Volume
1,574.00
52W Low
$13.06
Price
$13.79
Prev Close
$13.75
RNA Fundamentals
Open
$13.77
50D MA
$14.88
Beta
0.00
Avg. Volume
7.96M
Loading...
Loading...
News
all
press releases
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies Atrium Therapeutics Launches with Approximately $270 Million to Advance...
PR Newswire·18d ago
News Placeholder
More News
News Placeholder
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference Avidity Biosciences Announces Multiple Upcoming...
PR Newswire·19d ago
News Placeholder
Promising Pharmaceutical Stocks To Follow Now - February 26th
Eli Lilly and Company, Avidity Biosciences, Novo Nordisk A/S, AbbVie, Gilead Sciences, Abbott Laboratories, and Pfizer are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...
MarketBeat·19d ago
News Placeholder
Promising Medical Stocks To Follow Today - February 26th
Eli Lilly and Company, UnitedHealth Group, Arcellx, Avidity Biosciences, and Novo Nordisk A/S are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks...
MarketBeat·19d ago
News Placeholder
Avidity Biosciences (NASDAQ:RNA) Issues Quarterly Earnings Results
Avidity Biosciences (NASDAQ:RNA - Get Free Report) released its earnings results on Monday. The biotechnology company reported ($1.59) earnings per share for the quarter, missing analysts' consensus...
MarketBeat·20d ago
News Placeholder
Avidity Biosciences, Inc. $RNA Shares Bought by Vanguard Group Inc.
Vanguard Group Inc. grew its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 42.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC...
MarketBeat·20d ago
News Placeholder
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders PR...
PR Newswire·22d ago
News Placeholder
Rhumbline Advisers Decreases Stake in Avidity Biosciences, Inc. $RNA
Rhumbline Advisers lowered its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 9.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 158,071...
MarketBeat·22d ago
News Placeholder
Fiera Capital Corp Has $52.39 Million Position in Avidity Biosciences, Inc. $RNA
Fiera Capital Corp lifted its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 53.8% during the 3rd quarter, according to its most recent filing with the Securities and...
MarketBeat·25d ago
News Placeholder
Avidity Biosciences, Inc. $RNA Shares Acquired by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. lifted its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 173.2% during the third quarter, according to the company in its most recent...
MarketBeat·25d ago
<
1
2
...
>

Latest RNA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.